Bristol-Myers Ends Hepatitis C Drug Trial

Bristol-Myers announced it would permanently end clinical trials of its hepatitis C drug after a study participant died of heart failure, according to a Bloomberg Businessweek report.


Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

Earlier this months, the company suspended clinical trials of the drug BMS-986094, citing "the emergence of a serious safety issue." Until now, officials have stayed mum on the exact risk posed to patients.

In addition to the participant who died, eight others were hospitalized due to adverse reactions to the drug. Bristol-Myers is investigating what caused the hospitalizations, though heart and kidney toxicity could be a factor.

More Articles on Patient Safety:

Kansas Healthcare Providers Partner for Infection Prevention Education

Loyola University Receives Grant for Infection Prevention Education

University of Toledo Medical Center in Ohio Admits "Human Error" Caused Transplant Program Suspension

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast